Alliance Wealth Advisors LLC UT Acquires 199 Shares of Repligen Co. (NASDAQ:RGEN)

Alliance Wealth Advisors LLC UT raised its holdings in Repligen Co. (NASDAQ:RGEN) by 5.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 3,586 shares of the biotechnology company’s stock after purchasing an additional 199 shares during the quarter. Alliance Wealth Advisors LLC UT’s holdings in Repligen were worth $516,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. UMB Bank n.a. boosted its holdings in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 110 shares during the period. First Turn Management LLC bought a new stake in Repligen in the 3rd quarter valued at $13,202,000. Thrivent Financial for Lutherans grew its holdings in Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after buying an additional 36,773 shares in the last quarter. Geneva Capital Management LLC increased its position in Repligen by 8.5% during the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock worth $20,638,000 after buying an additional 10,908 shares during the period. Finally, TimesSquare Capital Management LLC boosted its position in shares of Repligen by 14.6% in the third quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company’s stock valued at $41,019,000 after acquiring an additional 35,115 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Up 0.1 %

RGEN stock opened at $160.02 on Wednesday. The firm has a 50-day moving average price of $154.78 and a 200-day moving average price of $148.32. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.97 billion, a P/E ratio of -432.47, a price-to-earnings-growth ratio of 4.67 and a beta of 0.99.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.23 EPS. As a group, equities research analysts anticipate that Repligen Co. will post 1.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RGEN has been the topic of a number of recent research reports. Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. HC Wainwright cut their price target on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Finally, Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $184.73.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.